In 2023, research on mice and rats suggested semaglutide — the powerful ingredient behind Wegovy and Ozempic — could raise the risk of one type of thyroid cancer: medullary thyroid cancer (MTC). Last ...

The EMA, as well as the FDA in the US, have approved labelling for Wegovy that mentions that semaglutide has been ... people with a family history of thyroid cancer. In a statement, the EMA ...

Still, definitely tell your healthcare provider if you have a personal or family history of thyroid cancer before starting semaglutide treatment. It’s possible to experience significant ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

semaglutide (the active ingredient in Rybelsus) caused thyroid tumors in mice and rats. Animal studies don’t always predict what will happen in people. And no cases of thyroid cancer have been ...

For instance, cancer researchers in India conducted a systematic review and meta-analysis of semaglutide and cancer ... including pancreatic and thyroid cancers. In another systematic review ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

Typically, semaglutide is subcutaneously administered ... gallbladder disease, medullary thyroid cancer, or type 2 multiple endocrine neoplasia were excluded from the study. Participants ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...